Here’s what happened when codeine was made prescription-only

Nicholas Buckley

3/10/2019 1:14:52 PM

Researchers have examined how the 2018 up-scheduling has affected Australia’s use of the traditionally popular painkiller.

Broken tablet
The 2018 switch resulted in a 50% drop in codeine overdoses and sales in Australia, researchers found.

Fears switching the painkiller codeine to a prescription-only medicine would lead to more people misusing stronger painkillers are unfounded, according to new research.

Our research, in the journal Addiction, found the 2018 switch resulted in a 50% drop in codeine overdoses and sales. There was also no increase in overdoses with stronger opioids or high-strength codeine, as some had feared.

How did we get here?
Australia has a love affair with codeine. It has historically been our most used opioid, and 2013 data showed we took more codeine as a country than the US, despite having roughly 7% the population.
However, from February 2018, you could only buy codeine in Australia with a prescription. Before then, you could buy low-strength codeine (up to 15 mg per tablet) in combination with paracetamol, ibuprofen and aspirin over the counter at pharmacies. Higher strength codeine has always required a prescription.
The 2018 change was not an overnight decision. Codeine has been on the government’s radar for over a decade; the Therapeutic Goods Administration (TGA) set up a codeine working party in 2008 in response to increasing misuse.
Codeine is an opioid analgesic, meaning people can become dependent on it, and there is a risk of harm from overdose.
There was also an earlier attempt at reducing harm when, in 2010, all codeine painkillers were moved behind the counter at pharmacies. Before that, the lower strength products could be picked up off the pharmacy shelf without consulting a pharmacist.
Unfortunately, our previous study showed this move to stocking codeine behind the counter had little impact. Other studies also showed that deaths from codeine continued to increase.
The 2016 National Drug Strategy Household Survey reported codeine available from behind the counter at a pharmacy was the most misused legal opioid in Australia and misuse was particularly common in adolescents.
This left the TGA with little choice but to bring Australia in line with most other countries that restrict codeine to prescription-only. The TGA announced the change in December 2016 following a lengthy consultation, and the change took effect on 1 February 2018.

Not everyone was happy
The announcement divided community and healthcare professional groupsPharmacy organisations opposed the change, whereas GPs were in favour.

There were also fears the change would lead to a massive burden on GPs as patients came to request codeine.

Some people were concerned the move would drive people to use higher strength codeine. This was because people wanting codeine would need to see their doctor, so they might request the stronger products that had always been prescription-only. 

There was also concern the change would push people towards even stronger painkillers, like oxycodone and morphine.

What happened next?
In our work at the NSW Poisons Information Centre, we get hundreds of calls about opioid overdoses every month. So we were keen to evaluate whether the change in codeine availability affected the number of overdoses. We, like others, were also worried there might also be unintended consequences of the change in its availability.

In the year after the change, we saw a 51% drop in codeine poisonings overall. This mainly affected low-strength preparations (the category no longer available without prescription), where poisonings dropped by 79%.

There was no increase in poisonings with high-strength codeine or other opioids. Similarly, sales data showed overall use of codeine dropped by almost 50%, with use of low-strength codeine most affected, dropping by 87%. Again, there was no increase in use of high-strength codeine.

Genetics are also important
Concerns over misuse and addiction were not the sole reason behind the change in codeine availability. A person’s response to codeine is determined by their genes, specifically a gene that codes for the enzyme CYP2D6. This enzyme activates codeine by converting it to morphine in the body.

So, depending on their DNA, some people don’t get any effect from codeine, some get a ‘normal’ effect, while others find it toxic at what is normally considered a safe dose.

The latter is the most dangerous scenario and has resulted in several deaths. This has included a newborn baby who died after their mother had a normal dose of codeine for pain after childbirth. The mother was later found to have the gene that results in excessive codeine activation, and a lethal dose of morphine was transmitted to her baby in her breast milk.

Even if the misuse problems disappeared overnight, people who advocated codeine be available only by prescription argued that a medicine with such a variable effect should only be available after seeing a doctor.

Unintended consequences of the codeine switch
Future research needs to look into possible unintended consequences of the change in codeine availability.

For instance, people may have switched to simple analgesics, like paracetamol and ibuprofen. These don’t have the same potential to be abused, are generally safer, and are more effective than low-strength codeine products. Yet they can still be toxic when overdosed.

Our research didn’t look at whether the codeine switch led to more people using paracetamol or ibuprofen, or were harmed by them.

Limiting availability works
Prescription drug misuse and overdoses are problems that are very much driven by drug availability. And when the availability of other medicines in Australia and internationally has been restricted, we’ve seen the benefits, namely reductions in misuse and poisoning.

This has happened with the opioid painkillets tramadol, hydrocodone and dextropropoxyphene, and the benzodiazepine aplrazolam.

Our study shows a good example of how effective simple strategies can be in tackling opioid misuse. Codeine is just one small piece of the puzzle, and we would like to see further investment and a systematic strategy to address causes of the rise in fatal poisonings from prescription drugs in the past decade.

We would like to see a national centre for poisoning research set up, which would bring together and support existing and new researchers. This would focus on preventing and managing poisoning, to provide a national response to this clinical and public health problem.

This article originally appeared in The Conversation. Read the original article.

Login below to join the conversation.

The Conversation

codeine over the counter up-scheduling

newsGP weekly poll What areas of healthcare were you hoping would get more funding in this year's Federal Budget?

newsGP weekly poll What areas of healthcare were you hoping would get more funding in this year's Federal Budget?



Login to comment

Dr Francisco Rodriguez-Letters   4/10/2019 6:46:10 AM

"Our research didn’t look at whether the codeine switch led to more people using paracetamol or ibuprofen, or were harmed by them."
I would consider this an immense oversight. So, in effect, this study didn't really prove any harm reduction whatsoever.

Dr Venkata Suman Musku   4/10/2019 7:36:49 AM

Very impressed with this evidence, in my practice I have not seen any increase in script request for low dose codeine products since change in legislation. Good to know about the gene connection . Can’t wait for emergency departments to minimise use of Endone .